AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca has sealed a $39 billion deal to ... Read More
Alexion Pharmaceuticals to acquire Portola Pharmaceuticals for $1.4bn
Alexion acquisition of Portola : Alexion Pharmaceuticals has agreed to acquire Portola Pharmaceuticals, a commercial-stage biopharma company focused on life-threatening blood-related disorders, for $1.41 billion. ... Read More
Alexion to acquire Achillion to strengthen rare diseases portfolio
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal ... Read More
Alexion Pharmaceuticals to acquire Syntimmune for $1.2bn to boost rare disease drug pipeline
In a significant move within the pharmaceutical industry, Alexion Pharmaceuticals, a leading global biopharma company, has announced its acquisition of Syntimmune, a Boston-based clinical-stage biotech ... Read More
Alexion Pharmaceuticals to acquire Wilson Therapeutics for $855m to enhance rare disease treatment options
In a significant move to expand its rare disease drug portfolio, U.S.-based Alexion Pharmaceuticals has announced an all-cash acquisition of Swedish pharmaceutical company Wilson Therapeutics ... Read More